MYBL2 haploinsufficiency increases susceptibility to age-related haematopoietic neoplasia
The haematopoietic system is prone to age-related disorders ranging from deficits in functional blood cells to the development of neoplastic states. Such neoplasms often involve recurrent cytogenetic abnormalities, among which a deletion in the long arm of chromosome 20 (del20q) is common in myeloid...
Saved in:
Published in | Leukemia Vol. 27; no. 3; pp. 661 - 670 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
01.03.2013
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The haematopoietic system is prone to age-related disorders ranging from deficits in functional blood cells to the development of neoplastic states. Such neoplasms often involve recurrent cytogenetic abnormalities, among which a deletion in the long arm of chromosome 20 (del20q) is common in myeloid malignancies. The del20q minimum deleted region contains nine genes, including
MYBL2,
which encodes a key protein involved in the maintenance of genome integrity. Here, we show that mice expressing half the normal levels of
Mybl2
(
Mybl2
+/Δ
) develop a variety of myeloid disorders upon ageing. These include myeloproliferative neoplasms, myelodysplasia (MDS) and myeloid leukaemia, mirroring the human conditions associated with del20q. Moreover, analysis of gene expression profiles from patients with MDS demonstrated reduced levels of
MYBL2
, regardless of del20q status and demonstrated a strong correlation between low levels of
MYBL2
RNA and reduced expression of a subset of genes related to DNA replication and checkpoint control pathways. Paralleling the human data, we found that these pathways are also disturbed in our
Mybl2
+/Δ
mice. This novel mouse model, therefore, represents a valuable tool for studying the initiation and progression of haematological malignancies during ageing, and may provide a platform for preclinical testing of therapeutic approaches. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 These two authors are co-senior authors. |
ISSN: | 0887-6924 1476-5551 |
DOI: | 10.1038/leu.2012.241 |